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The backbone of all colorectal cancer classifications including the consensus molecular subtypes (CMS) highlights microsatellite
instability (MSI) as a key molecular pathway. Although mucinous histology (generally defined as >50% extracellular mucin-to-tumor
area) is a “typical” feature of MSI, it is not limited to this subgroup. Here, we investigate the association of CMS classification and
mucin-to-tumor area quantified using a deep learning algorithm, and the expression of specific mucins in predicting CMS groups
and clinical outcome. A weakly supervised segmentation method was developed to quantify extracellular mucin-to-tumor area in
H&E images. Performance was compared to two pathologists’ scores, then applied to two cohorts: (1) TCGA (n= 871 slides/412
patients) used for mucin-CMS group correlation and (2) Bern (n= 775 slides/517 patients) for histopathological correlations and
next-generation Tissue Microarray construction. TCGA and CPTAC (n= 85 patients) were used to further validate mucin detection
and CMS classification by gene and protein expression analysis for MUC2, MUC4, MUC5AC and MUC5B. An excellent inter-observer
agreement between pathologists’ scores and the algorithm was obtained (ICC= 0.92). In TCGA, mucinous tumors were
predominantly CMS1 (25.7%), CMS3 (24.6%) and CMS4 (16.2%). Average mucin in CMS2 was 1.8%, indicating negligible amounts.
RNA and protein expression of MUC2, MUC4, MUC5AC and MUC5B were low-to-absent in CMS2. MUC5AC protein
expression correlated with aggressive tumor features (e.g., distant metastases (p= 0.0334), BRAF mutation (p < 0.0001), mismatch
repair-deficiency (p < 0.0001), and unfavorable 5-year overall survival (44% versus 65% for positive/negative staining). MUC2
expression showed the opposite trend, correlating with less lymphatic (p= 0.0096) and venous vessel invasion (p= 0.0023),
no impact on survival.
The absence of mucin-expressing tumors in CMS2 provides an important phenotype-genotype correlation. Together with MSI,
mucinous histology may help predict CMS classification using only histopathology and should be considered in future image
classifiers of molecular subtypes.
Modern Pathology; https://doi.org/10.1038/s41379-021-00894-8
INTRODUCTION
Colorectal cancers are a heterogeneous group of tumors, from the
histomorphological, clinical and molecular points-of-view. In terms
of molecular changes, one particularly well-described genomic
aberration is microsatellite instability (MSI), affecting ~15% of all
cancers1. Patients with sporadic MSI cancers have defects in DNA
mismatch repair (MMR) machinery, which is relevant for at least
three different scenarios. First, MSI status serves as a diagnostic
tool to help identify colorectal cancers arising from a possible
familial setting (e.g. Lynch syndrome)2. Second, in general,
patients with stage II colorectal cancers seem to derive a survival
benefit with MSI3. Third, evidence suggests that patients with MSI
colorectal cancers respond poorly to certain chemotherapies, but
may have remarkable positive responses to immunotherapy1,4.
The MSI status is therefore an important factor affecting treatment
decisions in colorectal cancer and is included in both pathological
and oncological guidelines (ESMO)5.
The MSI status also constitutes the backbone of all major
molecular classifications of colorectal cancer today, including the
2015 consensus molecular subtypes (CMS)6. The CMS classification
summarizes four major subgroups of colorectal cancers mainly
from the genetic and epigenetic perspectives, with impact on
clinical and therapeutic outcome7. CMS1 includes the hypermu-
tated, hypermethylated tumors with frequent BRAF mutation and
immune cell infiltrates. These are predominantly the MSI cancers.
CMS2 include tumors derived from canonical WNT signaling
pathway deregulation and have high frequency somatic copy
number alterations (37% of all cases). A metabolic subtype with
KRAS mutations and mixed MSI status is found in CMS3 (13% of
cases). Finally, the CMS4 cancers encompass those with
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mesenchymal and stem-cell like features, and leading to the worst
overall and recurrence-free survival.
Attempts have been made to predict MSI cancers using only
histopathological features of the cancer. In fact, experienced
pathologists can often identify MSI cases simply by glancing at the
hematoxylin & eosin (H&E) stained slide. In 2003, work by Jass and
colleagues led to the publication of the “MS-Path” score, namely a
model for identifying MSI-high, specifically Lynch syndrome
patients using a handful of clinical and histopathology features8.
These included the presence of Crohns’-like reaction, tumor
infiltrating lymphocytes and the presence of mucinous histology.
Mucin is not exclusively found in MSI-high patients though, and
the prognosis associated with mucinous histology in primarily
surgically treated colorectal cancer is unclear9. Moreover, the WHO
classification defines a mucinous tumor as having >50%
extracellular mucin to tumor area, which is not only arbitrary
but also challenging to report in many cases. Finally, mucin-
producing colorectal cancers are themselves heterogeneous and
show a wide range of mucin-to-tumor ratio.
In order to better understand the role of extracellular mucin in
colorectal cancer, we created a deep learning classifier to quantify
the extracellular mucin-to-tumor area ratio in two independent
cohorts (Bern n= 517, TCGA n= 412) and investigate the
genotype-phenotype correlation of mucin-to-tumor ratio with
CMS groups, MSI status and expression of mucin-producing genes.
METHODS
Cohorts
Cohort 1—Bern. A large retrospective cohort of 517 primary colorectal
cancer patients diagnosed at the Institute of Pathology between 2002 and
2018 and treated at the Insel Hospital Bern (Switzerland) were included in
this study. All preoperatively treated rectal cancer cases were excluded.
Histopathological characteristics were reviewed according to the TNM 7th
edition. These included pT and pN classifications, lymphatic, venous and
perineural invasion (L, V, and Pn classifications), distant metastasis (clinical
or pathologically confirmed at the time of first diagnosis), tumor budding
according to the ITBCC criteria10, the percentage of the tumor border with
expanding growth pattern, the Klintrup–Mäkinen score for peritumoral
inflammation and tumor grade. Histological subtype was determined
according to WHO (4th ed.) and a mucinous subtype was defined as >50%
extracellular mucin per tumor area. MMR-status was determined using
immunohistochemistry for the four MMR proteins, as is standard of
practice at our institute (MLH1, PMS2, MSH2, and MSH6). Cases were
considered MMR-deficient when at least 1 of these proteins was absent.
BRAF mutational status was obtained after VE1 immunohistochemistry, as
previously reported11. No distinction between familial and sporadic cases
was made. Clinical information included age at diagnosis, tumor size,
wherever available and gender.
From each case, 1–2 diagnostic tumor slides with H&E staining were
retrieved from the archives of the Institute of Pathology and digitized
using a slide scanner (3DHistech). The use of patient data and tissue have
previously been approved by the Ethics Committee of the Canton of Bern,
Switzerland (KEK2017-01783). All relevant guidelines of the Institute of
Pathology, University of Bern, Canton of Bern, Switzerland were followed
for the study.
Next-generation Tissue Microarray construction (ngTMA®): A
previously described next-generation Tissue Microarray using digital
pathology for annotation was constructed from these cases11, which is a
multi-punch tissue microarray containing cores from the tumor center and
invasion front.
Immunohistochemistry: All ngTMAs were sectioned at 2.5 μm. Stained
for MUC2 and MUC5AC was performed by automated staining using a
Leica BOND III (Leica Biosystems, Newcastle, UK) immunostainer. Tris buffer
(pH 9) at 95 °C for 30min was used for antigen retrieval (Leica Biosystems).
All tissue sections were incubated with the following primary antibodies:
MUC2 (catalog no. NCL-MUC2; NCL-MUC-2, clone Ccp58, 1:200 dilution,
Leica Microsystems), MUC5AC (catalog no. NCL-MUC5-AC; clone CLH2,
1:200 dilution, Leica Microsystems). Then, all samples were incubated with
HRP (Horseradish Peroxidase)-polymer for 15min and subsequently
visualized using 3,3-Diaminobenzidine (DAB) as brown chromogen (Bond
polymer refine detection, Leica Biosystems, Ref DS9800) for 10min.
MUC5AC and MUC2 were scored as positive or negative based on any
tumor cell staining or complete absence of staining, respectively. In the
case of multiple punches per tissue sample, we collated the results and if
positivity was seen in any of the samples, the whole case was considered
positive.
Cohort 2—TCGA. The Cancer Genome Atlas (TCGA) data12 from public
repositories at the National Institutes of Health (NIH; USA) was considered
in this study. This data source has 1735 H&E whole slide images (WSI),
clinical information and genomic data of 553 patients in two projects
TCGA-COAD (colorectal adenocarcinoma) and TCGA-READ (rectal adeno-
carcinoma), available at the GDC data portal (https://portal.gdc.cancer.gov).
The clinical information included age at diagnosis, gender, tissue location,
tumor size, prior treatment type. Some histopathological characteristics
such as pT and pN classifications, and tumor grade were also included.
From this resource, we created a sub-dataset, namely TCGA-412 which has
412 patients. Only cases with at least one WSI containing tumor tissues
and of good enough quality for analysis were kept. Cases labelled as
“preoperative therapy” were removed from the study. Cases with more rare
histological subtypes such as neuroendocrine tumors, or signet ring cell
tumors were excluded leaving only cases labeled strictly as “mucinous”
and “adenocarcinoma”, or non-mucinous. Totally, 871 H&E WSI of TCGA-
412 dataset were investigated in this study. All of 412 cases have CMS and
MSI labels retrieved from Sage Bionetworks Synapse which were built
using a gene expression–based subtyping algorithm6. The MSI labels were
double-checked with the PreMSIm and MSIseq13,14, two MSI prediction R
packages based on the expression profiling of a gene panel (exome-
sequenced tumors, respectively).
Cohort 3—CPTAC. A public dataset, namely The Clinical Proteomic Tumor
Analysis Consortium (CPTAC) from the National Cancer Institute (NCI; USA)
was also included. The 373 H&E WSIs of 106 colon adenocarcinoma
patients were downloaded from The Cancer Imaging Archive (TCIA)6. The
clinical, proteomic and genomic data are available at LinkedOmics (http://
linkedomics.org/cptac-colon/). Clinical information included age at diag-
nosis, gender, tumor site, vital status and some histopathological
characteristics such as pT and pN classifications, tumor stage, the presence
of vascular, lymphatic, perineural invasion or colon polyps and the
mutation status of POLE, KRAS, NRAS, BRAF, MLH1, MSH2, PMS2, MSH6. The
MSI status was detected by fluorescent PCR-based assay15. There were 85
patients assigned into four CMS groups using a classifier from Sage
Bionetworks Synapse based on the RSEM gene expression profiles from
RNA-Seq6. A sub-dataset with 231 H&E WSIs of these 85 patients with CMS
information was available. However, these images correspond to frozen
sections, rather than H&E from formalin-fixed paraffin embedded material
and we refrained from including the images into this study.
Weakly supervised tissues segmentation from prior
information in CRC
Here we propose a novel precise tissue segmentation of histopathology
images using deep learning, namely by Group Affinity Weakly Supervised
segmentation (GAWS). It processes one histopathology image and some
patches of prior tissue as input with three main steps. First, an output
image is created during a forward process by extracting the visual feature
of each pixel from a convolutional neural network and assigning it into
different clusters. Then, a target image is created by refining the output
image with the similarity constraints on prior tissue pattern, color, and
spatial distribution of pixels. Finally, a backpropagation process based on a
segmentation loss function evaluates the error signals between output and
target images, and updates the network parameters. Supplementary Fig. 1
shows the main schema of the proposed GAWS method. An example result
of final output of the proposed algorithm with the WSI is shown in Fig. 1.
Two cohorts are included in this study. Tissues vary significantly in
morphology, scale, texture and color distribution, which makes it difficult
to find a general pattern for each tissue type. Thus, a weakly supervised
segmentation is particularly well suited for these problems, i.e., we do not
know the optimal number of tissue types in the image. Prior tissue is
needed to guide the creation of a target image by forcing all pixels related
to this tissue into a same cluster label and guide the algorithm to select the
best candidates for segmentation. In practice, there are two ways to
perform the prior tissue selection. An expert pathologist manually selects a















few example patches of tissues of interest by using some stand-alone
software, such as QuPath16 and ASAP (https://github.com/
computationalpathologygroup/ASAP). On the other hand, existing auto-
matic extraction tools using deep learning to classify and locate the tissue
of interest can be applied17–19. Especially in our previous work19, we
proposed a system for tissue detection in WSI based on an ensemble
learning method with two raters, a VGG20 and a CapsuleNet21. Some
additional examples of the tissue segmentation output are shown in
Supplementary Fig. 2.
Statistical analysis
Descriptive statistics for all variables were carried out. To determine the
association between categorical variables, the Chi-square test was used.
For analysis of two continuous variables, the Spearman’s correlation
coefficient was performed and to evaluate the relationship between a
quantitative variable among different categories of another variable, the
Wilcoxon’s Rank Sum or Kruskal–Wallis test was performed. Receiver
Operating Characteristics (ROC) curve analysis was performed to determine
the most discriminating cut-off for MMR-deficiency in the Bern cohort,
determined to be 10%. Intra-observer agreement for % mucin values
between pathologists’ scores and algorithm was analyzed using the
Intraclass Correlation Coefficient (ICC), with values >0.8 considered
excellent. Survival analysis was carried out using log-rank statistics and
Kaplan–Meier curves as well as Hazard Ratios and 95% CI from Cox
regression analysis. P values were two-sided and considered significant
when p < 0.05.
RESULTS
Agreement between deep learning algorithm for mucin-to-
tumor area quantification and pathologists’ scores (Bern
cohort)
First, we tested the inter-observer agreement of extracellular
mucin component, recorded as the percentage of total tumor
area covered by extracellular mucin, between two pathologists.
One hundred and forty-nine H&E scans from the Bern cohort were
used for this purpose. The ICC was 0.92, indicating excellent
agreement. We next tested the unsupervised GAWS algorithm
against the scores from both pathologists. Again, results were
excellent, with pathologist 1 ICC= 0.915 (95% CI: 0.885–0.937)
and pathologist 2 ICC= 0.923 (95% CI: 0.896–0.943). Based on
these results, we confidently applied the algorithm to the
remaining 775 H&E slides from the Bern cohort, and 871 slides
from the TCGA cohort. In the case where more than one slide/
case was available, the largest value across all slides was used for
further analysis.
Association of extracellular mucin, CMS and outcome in the
TCGA cohort (Table 1)
In the TCGA cohort, an association between TNM stage and CMS
was observed. CMS2 and CMS4 tumors were more frequently stage
IV (17.8 and 18.2%) compared to CMS1 (4.4%) and CMS3 (3.4%),
while stage I tumors were most often CMS3 (p < 0.0001). The
interconnectivity between CMS and stage has recently also been
reported in this cohort22. MSI-H was observed in CMS1 (81.4%) and
CMS3 (19.7%), and rarely in CMS2 and CMS4 (1.2% and 5.4%,
respectively) (p < 0.0001). Similarly, tumors with mucinous histologi-
cal subtype were observed in CMS1 (25.7%) and CMS3 (24.6%) and
less frequently in CMS4 (16.2%). Of the three cases declared as
mucinous in CMS2, our algorithm detects no mucin, which was
confirmed by evaluating the image by pathologist. These tumors are
likely mislabeled, signifying that CMS2 tumors exclude those with
mucinous subtype. These results are again supported by evaluating
the percentage of extracellular mucin/tumor area, showing similar
mean values for CMS1 and CMS3 (20.9 and 20.4%), followed by
CMS4 (18.8%) and low-to-no mucin in CMS2 (1.8%).
Although overall, no significant difference was noted between
non-mucinous and mucinous cancers, pronounced differences
were observed in stage II and CMS3 subgroups. In stage II
cancers, mucinous histology leads to poor 5-year OS (non-
mucinous vs mucinous cancer 94.5% and 76.5% respectively, p
= 0.0276) (Supplementary Fig. 3A, B). Similarly, in CMS3 patients
with mucinous cancers do significantly worse than patients with
non-mucinous cancers (58.5% versus 95.2% 5-year OS; p=
0.0052). However, in both cases, the impact of mucinous
histology was not independent of postoperative therapy
information, when adjusting confounding. Details can be found
in Supplementary Table 1.
Subgroup analysis of MSI and MSS tumors by mucinous
histology and CMS groups
MSI-H tumors are not exclusive to the CMS1 subgroup. They occur
albeit with less frequency in CMS3 and only rarely in CMS2 and
CMS4. Mucinous histology seems to be independent of MSI status
Fig. 1 Example of tissue detection in H&E CRC slides using the GAWS algorithm, with mucin in purple, tumor in red, normal tissues in
yellow, background and artifact in cyan. The number of tissue classes can be modified by changing the number of cluster parameter of the
proposed algorithm.
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(Fig. 2). We looked at the data in the TCGA cohort two ways. In the
first approach using the TCGA cohort, 21 mucinous cancers were
MSI compared to 33 MSS. Observing the results, we then used the
ROC-derived threshold value of 10% to classify tumors as low/high
mucin. 57% of MSI tumors had >10% extracellular mucin in contrast
to 27% which are classified as “mucinous” cancers. In the MSS, 17.9%
have >10% extracellular mucin and 9.9% (n= 33) are classified as
having mucinous histology. Of these, 15 are CMS4 and 14 are CMS3
tumors. Figure 2 also shows the exact values of extracellular mucin
as a function of the number of patients (density) with each value.
Here, results clearly support that the distribution of mucin
throughout CMS1 and CMS3 covers all ranges of values, that
CMS2 is a low-to-no mucin-producing group and finally that
CMS4 shows a bimodal distribution of mucin values.
Association of expression of mucin-associated genes and CMS groups
in TCGA. In order to validate the association of mucin detected
by our deep learning classifier and CMS groups, we used a second
complementary approach by analyzing the TCGA and CPTAC
cohorts for gene expression and protein expression namely for
four well-known mucin-related genes: MUC2, MUC4, MUC5AC and
MUC5B. The expression of mRNA (TCGA) of all the four mucin-
related genes is at significantly lower levels or nearly absent in
CMS2 (Fig. 3), in line with the results from the evaluation of our
images. For protein expression (CPTAC), obtained through tandem
mass tag labeling, the differences were less pronounced for
MUC5AC and MUC5B, where a handful of samples in the CMS2
group had high expression levels (See Supplementary Fig. 4 for
CPTAC data).
Clinical impact of mucin and mucin-related proteins in the
Bern cohort
Associations of mucinous histology and extracellular mucin with
clinicopathological features. Mucinous histological subtype, as
taken from diagnostic reports, was only associated with a less
advanced pT category. The average percentage of mucin in these
cases was 63%. Evaluating the result of the AI algorithm shows
that a higher amount of extracellular mucin is related to right-
sided tumor location (p= 0.0026), more advanced pT stage (p=
0.0485), higher tumor grade (p < 0.0001), but less venous invasion
(p= 0.0039) and a higher percentage of expanding tumor border
(p= 0.0001). The mean percentage of mucin in MMR-deficient
tumors was 27.1% compared to 8.4% in MMR-proficient cases
(p= 0.0001). Using a 10% cutoff to declare a case as “high” mucin,
the above associations were maintained. In addition, a higher
percentage of mucin correlated with lower tumor budding (p=
0.0241), higher Klintrup–Mäkinen score (p= 0.0577) and BRAF
mutation (p= 0.0329).
Clinical impact of MUC5AC and MUC2 in colorectal cancer.
MUC5AC and MUC2 were analyzed on an ngTMA of 337 patients
(Fig. 4). Expression of both proteins was associated with mucinous
histology (p < 0.001) (Table 2). MUC5AC was additionally asso-
ciated with right-sided tumor location (p= 0.01), higher pT (p=
Table 1. Association of CMS groups with TNM stage, MSI status, histological subtype and percentage of extracellular mucin.
TCGA CPTAC
CMS1 CMS2 CMS3 CMS4 p value CMS1 CMS2 CMS3 CMS4 p value
TNM stage
I 12 (17.3) 35 (21.5) 18 (30.5) 7 (6.4) <0.0001 0 (0.0) 4 (12.1) 7 (43.8) 1 (4.5) <0.0001
II 40 (58.0) 59 (36.2) 25 (42.4) 40 (36.4) 9 (64.3) 14 (42.4) 5 (31.3) 7 (31.8)
III 14 (20.3) 40 (24.5) 14 (23.7) 43 (39.1) 5 (35.7) 12 (36.4) 4 (25.0) 12 (54.5)
IV 3 (4.4) 29 (17.8) 2 (3.4) 20 (18.2) 0 (0.0) 3 (9.1) 0 (0.0) 2 (9.1)
Total no. cases 69 163 59 110 14 33 16 22
MSI status
MSI 57 (81.4) 2 (1.2) 12 (19.7) 6 (5.4) <0.0001 14
(100.0)
0 (0.0) 4 (25.0) 3 (13.6) <0.0001
MSS 13 (18.6) 168 (98.8) 49 (80.3) 105 (94.6) 0 (0.0) 33
(100.0)
12 (75.0) 19 (86.4)
Total no. cases 70 170 61 111 14 33 16 22
Histology
Mucinous 18 (25.7) 3 (1.8)a 15 (24.6) 18 (16.2) <0.0001 2 (14.3) 5 (15.2) 8 (53.3) 2 (9.1) <0.0001
Adenocarcinoma (non-
mucinous)
52 (74.3) 167 (98.2) 46 (75.4) 93 (83.8) 12 (85.7) 28 (84.8) 7 (46.7) 20 (90.9)
Total no. cases 70 170 61 111 14 33 16 22
%-mucin
Mean 20.9 1.8 20.4 18.8 8.8 3.8 14.2 8.9 0.3095
Median 7.0 0 7.6 0 <0.0001 2.7 0 0.8 0
Min–Max 0–95.1 0–34.5 0–93.1 0–97.7 0–52.9 0–62.2 0–95.5 0–43.2
Total no. cases 70 170 61 111 14 33 16 22
Cutoff mucin
<10% 36 (51.4) 160 (94.1) 33 (54.1) 79 (71.2) <0.0001 9 (64.3) 30 (90.9) 13 (81.3) 16 (72.7) 0.1474
>10% 34 (48.6) 10 (5.9) 28 (45.9) 32 (28.8) 5 (35.7) 3 (9.1) 3 (18.8) 6 (27.3)
Total no. cases 70 170 61 111 14 33 16 22
aThese three cases were verified by an expert pathologist who in fact confirmed the result of the algorithm, namely that all three cases were not mucinous
(<50% mucin).
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0.0073), more frequent distant metastasis (p= 0.0334), higher
tumor grade (p < 0.0001), frequent BRAF mutation (p < 0.0001) and
MMR-deficiency (p < 0.0001). Positive expression was an unfavor-
able prognostic factor (5-year OS, 44% versus 65% for positive and
negative staining) (Fig. 5). MUC2 expression correlated with higher
tumor grade (p= 0.0044), a more expansive border (p= 0.044) but
with less lymphatic and venous invasion (p= 0.0096, p= 0.0023,
respectively). A trend toward more frequent MSI was found
(p= 0.0567).
DISCUSSION
In this study, we combine histomorphology with deep learning
and genomics to validate the relationship of mucin-producing
Fig. 2 Subgroup analysis of MSI/MSS tumors by mucinous histology and CMS groups. (Pie-Chart) Distribution of CMS classifications by MSI
status in (first row) mucinous and non-mucinous (adenocarcinoma) colorectal cancers and (second row) high or low mucin content based on
10% threshold from the TCGA database. (Line-Chart) Plot of the density of each mucin score by MSI status across each CMS group in mucinous
samples (mucin score >10%). The x-axis shows the %-mucin detected by the AI algorithm with each line representing a sample with that
value. In CMS1 and CMS3, mucin values are distributed throughout the range of possible values from 0–100%, while no case in CMS2 reaches
the threshold of 50% to be declared as “mucinous”. CMS4 points towards a bimodal distribution of mucin scores.
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colorectal cancers and CMS classification. The novel findings of
this study suggest that CMS2 cancers generally lack mucin, which
is reflected not only in the quantification of extracellular mucin to-
tumor area resulting from our algorithm, but also in analysis of
mucin-related genes and proteins in two different publicly
available datasets. We additionally show that although mucin is
a feature of MSI cancers, it is by far not limited to the subgroup.
Moreover, the specific MUC5AC protein expression is associated
with aggressive cancers and worse overall survival (Fig. 5).
In a first step, we developed a novel deep learning algorithm
using a segmentation algorithm to help quantify the extracellular
mucin across two large cohorts (Bern and TCGA) and takes
advantage of weakly supervised learning from a predefined tissue
pattern without any pre-trained parameters of the neural network
Fig. 3 Violin plots of mucin-related gene expression data from the TCGA-COAD and TCGA-READ datasets. Values on the y-axis represent
log scale of the normalized mRNA sequencing counts. On the x-axis, different CMS types of primary tumors are shown along with normal
tissue sample values.
Fig. 4 Representative immunohistochemistry images for MUC5AC and MUC2 in colorectal cancer. MUC5AC positive (A) and negative (B),
MUC2 positive (C) and negative (D).
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or training data. The proposed method can be considered as a
potential visual scoring tool with an efficiency in processing time
and memory needed to support pathologists and to overcome the
practical limitations of visual scoring. Since the inter-observer
agreement between pathologists and the proposed algorithm was
excellent (ICC= 0.917), we applied it across all of our images,
totaling >1500 slides.
In a second step, we evaluated the association of extracellular
mucin/tumor area and the CMS classification on the TCGA dataset.
Our results clearly show that (1) CMS2 tumors lack mucin, (2)
mucin-producing tumors can be CMS1, CMS3 and CMS4, (3)
mucin-producing tumors may or may not be MSI and (4) CMS4
cancers can be separated into low- or high-mucin-producing
cancers.
Our results indicate that extracellular mucin quantified on the
H&E slide by histology can be an indication of the CMS group,
especially for cancers that are MSS. Such genotype-phenotype
correlations have already been described, albeit without the use of
digital pathology. Jenkins and colleagues in 2005, developed the
MS-Path score using a multivariable logistic regression model for
Table 2. Association of MUC5AC and MUC2 expression in colorectal cancer using a multiple punch ngTMA (Bern cohort, total 373 patients).
MUC5AC MUC2
Feature Negative (n= 306) Positive (n= 29) P value Negative (n= 221) Positive (n= 116) P value
Age (years) Mean 69.4 70.4 0.797 69.8 68.9 0.6564
Gender Female 117 (38.0) 16 (55.2) 0.0703 86 (38.9) 47 (40.5) 0.7748
Male 191 (62.0) 13 (44.8) 135 (61.1) 69 (59.5)
Histological subtype Non-
mucinous
283 (92.5) 21 (72.4) 0.0004 210 (95.0) 94 (82.5) 0.0002
Mucinous 23 (7.5) 8 (27.6) 11 (5.0) 20 (17.5)
Tumor location Left 137 (46.3) 3 (12.5) 0.001 99 (46.7) 41 (38.0) 0.154
Rectum 57 (19.3) 4 (16.7) 42 (19.8) 19 (17.6)
Right 102 (34.5) 17 (70.8) 71 (33.5) 48 (44.4)
pT pT1 4 (1.3) 2 (6.9) 0.0073 1 (0.5) 5 (4.4) 0.0813
pT2 51 (16.8) 2 (6.9) 34 (15.5) 19 (16.7)
pT3 168 (55.3) 11 (37.9) 120 (54.8) 59 (51.8)
pT4 81 (26.6) 14 (48.3) 64 (29.2) 31 (27.2)
pN pN0 134 (44.2) 11 (40.7) 0.0652 89 (40.8) 56 (50.0) 0.2773
pN1 102 (33.7) 5 (18.5) 74 (33.9) 33 (29.5)
pN2 67 (22.1) 11 (40.7) 55 (25.2) 23 (20.5)
pM or CM Absent 227 (73.7) 16 (55.2) 0.0334 10 (72.4) 83 (71.6) 0.8692
Present 81 (26.3) 13 (44.8) 61 (27.6) 33 (28.4)
Tumor grade G1 8 (2.6) 0 (0.0) <0.0001 3 (1.4) 5 (4.3) 0.0044
G2 239 (77.9) 13 (44.3) 177 (80.5) 75 (64.7)
G3 60 (19.5) 16 (55.2) 40 (18.2) 36 (31.0)
Lymphatic L0 86 (30.6) 7 (30.4) 0.9864 50 (25.5) 43 (39.8) 0.0096
L1 195 (69.4) 16 (69.6) 146 (74.5) 65 (60.2)
Venous V0 125 (44.2) 12 (52.2) 0.4578 76 (38.4) 61 (56.5) 0.0023
V1 158 (55.8) 11 (47.8) 122 (61.6) 47 (43.5)
Perineural Pn0 223 (80.8) 16 (69.6) 0.1963 148 (76.7) 91 (85.8) 0.0584
Pn1 53 (19.2) 7 (30.4) 45 (23.3) 15 (14.2)
Klintrup–Mäkinen KM0 23 (8.4) 3 (13.0) 0.1995 19 (9.9) 7 (6.6) 0.2317
KM1 118 (42.9) 9 (39.1) 81 (42.2) 46 (43.4)
KM2 108 (39.3) 6 (26.1) 68 (35.4) 46 (43.4)
KM3 26 (9.5) 5 (21.7) 24 (12.5) 7 (6.6)
Tumor border %
expansive
Mean 44.6 49.5 0.5114 42.1 50.2 0.044
Nr. ITBCC buds Mean 9.3 10.7 0.3057 9.7 9.0 0.2691
Post-op therapy Absent 234 (76.0) 20 (69.0) 0.4023 165 (74.7) 89 (76.7) 0.6761
Present 74 (24.0) 9 (31.0) 56 (25.3) 27 (23.3)
BRAF VE1 Wild-type 187 (92.1) 2 (12.5) <0.0001 132 (88.0) 57 (82.6) 0.2811
Mutation 16 (7.9) 14 (87.5) 18 (12.0) 12 (17.4)
MSI Deficient 16 (9.2) 11 (68.8) <0.0001 14 (10.9) 13 (21.3) 0.0567
Proficient 157 (90.8) 5 (31.2) 114 (89.1) 48 (78.7)
OS 5-years % 65.4 44.0 0.0039 63.6 63.4 0.9707
Bold values indicate statistical significance p < 0.05.
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the prediction of Lynch syndrome patients, based solely on two
clinical (age and tumor location) and four histopathological
features (histological subtype including mucinous, tumor grade,
Crohns’-like reaction and tumor infiltrating lymphocytes), reaching
an AUC value of >0.88. In fact, well-trained gastrointestinal
pathologists can, with high accuracy, predict the occurrence of
MSI-high colorectal cancers simply from the impression of these
features in an H&E slide. In a second publication, Jass and
coworkers found that mucinous differentiation of colorectal
cancers was significantly greater in tumors with KRAS mutations,
which is also a frequent feature of CMS36,23. Jang and colleagues
apply deep learning to images from the TCGA cohort with the aim
of differentiating between non-mutated and KRAS mutated
colorectal cancers24. They extract information on APC, KRAS,
PIK3CA, SMAD4, and TP53 mutations and show a modest degree of
accuracy in terms of classification. Echle and colleagues performed
MSI detection from 8836 colorectal cancers of mixed stages from
multiple institutions in Europe, UK, and USA25. They impressively
achieve clinical grade performance with an AUC of 0.92 in the
development cohort and 0.95 in the validation cohort although
the histological features leading to the classification are not
discussed. Extending the idea of genotype-phenotype correlation
across many tumor types, Noorbakhsh et al. observe similar
histological patterns between TP53 mutated cancers independent
of tumor entity, and report whole slide image- and cross-tissue
AUC values of 0.65–0.826.
In this study, we go one step further to analyze two different
publicly available datasets with genomic or proteomic data and
CMS classification. We analyzed four common mucin-related
genes, namely MUC2, MUC4, MUC5AC and MUC5B. Both analyses
on the gene expression (TCGA) and protein expression (CPTAC)
level clearly show that CMS2 tumors demonstrate low expres-
sion of all genes or proteins, followed by CMS4 tumors,
explained by the bimodal distribution of mucin within this
particular CMS. We also note a high expression of MUC5AC
protein (CPTAC) in CMS1, an entirely MSI-H group and high
MUC2 expression in CMS3. In fact, our results indicate that MUC2
expression may play a role in differentiating CMS3 and CMS4
cancers. These results are again reflected in our ngTMA
immunohistochemistry analysis, showing a strong association
between MMR-deficiency and MUC5AC expression. Interestingly,
although MUC5AC positive cancers are associated with sig-
nificantly worse overall survival in patients, MUC2 cancers show
a much more indolent phenotype. This is in line with in vitro
studies showing that MUC5AC expression enhanced cell
invasion and migration, decreased apoptosis and led to
tumorigenesis and appearance of metastatic lesions in ortho-
topic mouse models27. In addition, MUC5AC leads to resistance
to 5-FU based chemotherapy, reflecting the situation of patients
in CMS1 with predominantly MSI-H cancers6. Moreover, a
systematic review including MUC2 indicates an improved
outcome with MUC2 over-expression in colorectal cancer
patients28 again, in line with our findings.
In fact, several additional features from the histology seem to be
closely related to the CMS classifications. Sirinukunwattana et al.
apply deep learning methods to H&E images of colorectal cancer
cohorts with known CMS analysis29. They achieve excellent AUC
values using this image CMS (imCMS) classifier and highlight
common histopathology features that seem to occur in each
group. For example, they show that mucinous differentiation and
lymphocytic infiltration are common in imCMS1, whereas a
prominent desmoplastic stroma occurs in imCMS4. They note
cribriform growth patterns and comedo-like necrosis in imCMS2
while imCMS3 is characterized by mucin-filled glandular struc-
tures. Our previous work on tumor budding in several cohorts with
CMS classification also identifies high-grade budding as a feature
closely related to CMS430.
Finally, although the focus of this study was not on the diagnostic
reporting of mucinous histology, some observations can be made.
“Mucinous” cancers in both cohorts are not always in line with the
WHO definition of >50% extracellular mucin, especially in the TCGA
cohort, where the median extracellular value is 50% (indicating that
half the so-called mucinous cases are below that value). One
possibility is that the images included for the dataset are not the
most representative of that cancer. Our mucin-detection algorithm
also found discrepant cases, which were confirmed by an expert
pathologist. It also suggests that pathologists’ impression of what
constitutes a mucinous cancer relies also on additional histological
impressions, not only on mucin content.
To summarize, extracellular mucin detected by deep learning
from an H&E image may help to differentiate between CMS
groups, with CMS2 tumors generally lacking mucin, independently
of MSI status. Together with MSI, mucinous histology may help
predict CMS using only histopathology and should be considered
in future image classifiers of molecular subtypes.
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